Anthony Vendetti: Okay. So, neither of them are started at this point, okay.
Steven LaRosa: That’s correct.
James Frakes: That’s correct. We are poised – I have been really pushing hard on this, Anthony, since I was named interim CEO. And we have come a long way on the R&D efforts. They couldn’t even count the extracellular PD-L1 on the extracellular vesicles two months ago, and now they can count the total aggregates, but they have – it’s just inconclusive. That’s why we are engaging outside labs to get to the bottom of exactly where we are.
Steven LaRosa: Yes. And to reiterate Jim’s point, so there is a whole – and you can imagine, there is a whole book of activity that have to be done to start a trial. And so we have been pushing to get every one of those dots so that once we have this data, we can go if it is fit to go.
Anthony Vendetti: Understood. Okay. And then lastly, I think you did mention at the end of your prepared remarks, an update on the organ transplant progress. Is that – maybe just give me a little more color on that. Is that I know the oncology is taking priority, but maybe just an update on where that’s at.
James Frakes: Well, I did push to make the oncology effort as the highest priority, but there was momentum with the organ transplant work. We have generated additional data. It’s pretty interesting stuff. And we do plan to write one or more articles. We have the data. We are far enough along with the oncology studies that the – some of the more senior people can move their – wrap their head around getting the articles written and try to get this published. So, we haven’t stopped that work. We may very well have things to talk about on future calls on the organ transplantation trend.
Anthony Vendetti: Are you still working with 34 lives on the transplant side?
James Frakes: We are. They have been busy getting their clinical trial going. We have been busy with the oncology stuff. But yes, we are still – we have a collaboration agreement with them. And now that the – I don’t really know where they are with their – they are a private company. We couldn’t talk about it publicly, even if we knew. But we are still working with them and I think the time to move forward may be coming soon. They may have gotten things going, but I don’t know. It’s not our business.
Anthony Vendetti: Okay. Great. Got it. Thanks for your update. I will hop back in the queue.
James Frakes: Thank you, Anthony.
Operator: Thank you. And ladies and gentlemen, this concludes the question-and-answer session. I would like to turn the conference back over to Jim Frakes for closing remarks.
James Frakes: Thank you again for joining us today to discuss our quarter end results. We look forward to keeping you up-to-date on future calls. Bye.
Operator: Thank you. This concludes today’s conference call. We thank you all for attending today’s presentation. You may now disconnect your lines and have a wonderful day.
